Preclinical assessment of dual CYP26[A1/B1] inhibitor, DX308, as an improved treatment for keratinization disorders.

J G S Veit,Y Poumay, D Mendes,J Kreitinger,L Walker,A Paquet, C Menigot, F Zolezzi,A S Paller,P Diaz

Skin health and disease（2021）

引用 2|浏览3

暂无评分

摘要

These preliminary studies suggest that DX308 is an efficacious topical therapeutic with a favourable metabolic and safety profiles. DX308 may present an improved therapeutic alternative for the treatment of keratinization disorders and other retinoid-responsive skin ailments.

查看译文

AI 理解论文

溯源树

样例

生成溯源树，研究论文发展脉络

Chat Paper

正在生成论文摘要